Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AASLD Briefs: Hepatitis C

Executive Summary

Presentations at the American Association for the Study of Liver Diseases conference included anticipated data from Gilead in hepatitis C genotype 3 patients, results from the COSMOS trial pairing Gilead’s sofosbuvir with Janssen’s simeprevir, Phase II data for Merck’s two-drug DAA combo and findings from an HCV collaboration by Boehringer Ingelheim and Presidio.

You may also be interested in...



Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations

DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.

Teva: Biosimilars In The US Will Become Like Complex Generics

With a couple of major partnerships and a stable of internal projects, Teva expects to play a role in the “majority of meaningful US biosimilar launches in the next five-to-eight years,” executive vice-president for North America commercial Brendan O’Grady told Generics Bulletin in an exclusive interview.

After COVID-19, Consumer Health Firms Need To Rethink Their Innovation Strategies

Given the scale of changes wrought by the coronavirus, IQVIA Consumer Health advises OTC companies to re-think their innovation strategies and consider “new and maybe more risky approaches,” such as Rx-to-OTC switch, digitalization and personalization.  

Topics

Related Companies

UsernamePublicRestriction

Register

PS055744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel